Item 7.01. Regulation FD Disclosure.

On January 9, 2023, Sage Therapeutics, Inc. (the "Company") made available an updated corporate presentation, which it plans to use for meetings with investors and analysts at the 41st Annual J.P. Morgan Healthcare Conference. A copy of the presentation is being furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On January 8, 2023, the Company issued a press release titled "Sage Therapeutics to Provide Update on 2023 Key Initiatives at J.P. Morgan Healthcare Conference." A copy of the press release is filed as Exhibit 99.2 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

Exhibit
  No.       Description

99.1          Corporate Presentation dated January 2023.

99.2          Press release issued by Sage Therapeutics, Inc. on January 8, 2023.


104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses